Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ptc Therapeutics (PTCT) Shares Outstanding (Diluted Average) (2019 - 2024)

Ptc Therapeutics has reported Shares Outstanding (Diluted Average) over the past 6 years, most recently at $76.8 million for Q4 2024.

  • Quarterly results put Shares Outstanding (Diluted Average) at $76.8 million for Q4 2024, up 2.68% from a year ago — trailing twelve months through Dec 2024 was $76.8 million (up 2.68% YoY), and the annual figure for FY2024 was $76.8 million, up 2.68%.
  • Shares Outstanding (Diluted Average) for Q4 2024 was $76.8 million at Ptc Therapeutics, roughly flat from $76.7 million in the prior quarter.
  • Over the last five years, Shares Outstanding (Diluted Average) for PTCT hit a ceiling of $76.8 million in Q4 2024 and a floor of $66.0 million in Q4 2020.
  • Median Shares Outstanding (Diluted Average) over the past 5 years was $71.7 million (2022), compared with a mean of $72.9 million.
  • Biggest five-year swings in Shares Outstanding (Diluted Average): rose 12.17% in 2020 and later increased 1.41% in 2022.
  • Ptc Therapeutics' Shares Outstanding (Diluted Average) stood at $66.0 million in 2020, then rose by 6.72% to $70.5 million in 2021, then grew by 1.79% to $71.7 million in 2022, then grew by 4.34% to $74.8 million in 2023, then rose by 2.68% to $76.8 million in 2024.
  • The last three reported values for Shares Outstanding (Diluted Average) were $76.8 million (Q4 2024), $76.7 million (Q3 2024), and $76.6 million (Q2 2024) per Business Quant data.